Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
US9956305B2 · kind B2 · utility
7Cited by
6References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 4, 2015 |
| Grant date | May 1, 2018 |
| Priority date | — |
| Expiry date | Oct 27, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.